Trial Funding & Business Investment
MBOS have been working privately and personally funding trials since 2010. Some of these results have been profound, and we have not been able to find anything like them with children this old in the scientific and medical literature.
​
We have reached the stage where - in order to proceed - we need to seek two areas of funding, one research-based to confirm the efficacy of the therapy model in a broader evidence-based context. This will allow us to satisfy requirements for healthcare regulators and the broader scientific community. The other area is business funding to complete commercial product readiness and begin delivery.
​
Our solution addresses an expanding global problem already involving more than 40 million autistic individuals and their families. The increasing rate of diagnosis, and current lack of adequate treatment has turned this into a socio-economic concern consuming ever larger amounts of global healthcare, government and personal spending. It appears that Microbaric® Oxygen Therapy provides the opportunity to change the trajectory of autism and its personal, social, and economic impact.
​
We encourage you to check out the testimonials from the mothers HERE.
​
​
Research / Trial Funding
This is an opportunity for research institutes and funding foundations to be part of a ground breaking effort to change the game and outcome for autism impacting millions of families and global healthcare budgets.
Our intention is to conduct gold standard research through a multi-site/multi-country randomized, prospective, double-blind trial (e.g., USA, UK, and Canada). We have written the clinical protocol for the trial and had approval to proceed to formal ethical review from one country’s healthcare regulation body already.
Interestingly and, perhaps, fortuitously, this research on autism comes at a time when the world’s attention on medical research has recently been focused on how human and animal cells sense and respond to low or inadequate oxygen levels. For their work in this area, three scientists shared the 2016 Robert Lasker Basic Medical Research Award. As described in our newly published peer-reviewed paper, it appears that autism is related to regional central nervous system hypoxia and hypometabolism. Similarly, several scientists have recently hypothesized that other neurological conditions such as neurodegeneration, cognitive impairment, and Alzheimer’s disease share similar underlying causes.
​
​
If you represent a foundation or university with a high impact focus on Autism then we'd love to hear from you.
Business Development Funding
Our work so far has created a trademarked term and new patents in regards to IP for the products and treatment process. We have developed advanced prototypes of a more user-friendly system and a clear plan for next-step actions to make the Microbaric® Oxygen Systems (MBOS) products ready for market.
We have plans for further product development and developments for other use cases in relation to neurological and other disorders including non-invasive ventilation now increasingly employed in combatting COVID-19.
We seek Impact Investors who themselves are on a mission to make the world a better place, that will see MBOS both as a business opportunity, but also recognise the chance to build a positive legacy by
-
establishing a new standard of care for autism
-
developing the market for non-invasive ventilation (e.g. COVID-19)
-
establishing new research in oxygen physiology
-
creating new care options for conditions such as Alzheimer's, stroke, wound care and more.
​
If you are an impact investor or institution with experience in healthcare, autism, neurological function or related - then we'd welcome the chance to explore business partnership.
